Upcoming events – Phase III data for Chiasma and Novartis
Chiasma hopes to be able to file its oral acromegaly therapy by year-end, and Novartis wants to shore up its MS franchise.
The $100,000 problem gene therapy companies would rather not mention
The high doses of recently studied gene therapies threaten manufacturing problems that few have fully considered.
